When a Sector Loses Value but Keeps Hiring
Portugal’s community-pharmacy labor market is the subject of this series, and its central puzzle is unusually revealing: after reforms reduced the value created by retail pharmacies, pharmacists’ wages fell sharply while employment continued to grow. The question is not simply why pay went down. It is how an industry-wide shock was distributed among firms, incumbent workers, new hires, and future entrants—and what that distribution tells us about labor markets when workers cannot easily carry their skills elsewhere. Understanding that chain gives readers a better way to judge whether a falling wage bill signals mass job destruction, a negotiated transfer, or both.
The case matters because the usual picture of an industry in trouble is incomplete. When demand or productivity falls, we often expect employers to cut headcount first and wages second. But a sector can also preserve or expand its workforce by lowering the price of labor, especially when workers have limited outside options and a steady stream of newly qualified people is still entering. That outcome may look reassuring in an employment chart while concealing a substantial transfer from established pay scales to newer cohorts.
The Portuguese pharmacy puzzle
The shock began in a highly regulated market. Portuguese community pharmacies bought prescription drugs at regulated wholesale prices and dispensed them under formulas that limited the markup they could charge. The government’s reforms during and after the 2010 financial crisis changed several parts of that system: wholesale prices were reduced, allowed retail margins were cut, generic substitution was encouraged, and the rules for reference pricing and patent expiry changed.
The effect on the economics of filling a prescription was large. Average pharmacy margin per filled prescription fell from €2.14 in 2010 to €1.24 in 2014, a nominal reduction of 42 percent. The study reports that, after accounting for consumer-price changes, the reduction in the price component of real value added was about 48 percent. Its broader measures show real value added per pharmacist falling by roughly one-third, or about 35 percentage points from its 2009 level, during the reform period. These are related but not identical measures: the first concerns the margin on a prescription, while the second also depends on the number of prescriptions, the mix of products, and the workers counted.
The distinction is important because a pharmacy does not create value simply by employing a pharmacist. In the paper's simplified framework, value added per pharmacist reflects both how many prescriptions the workforce handles and the net margin attached to those prescriptions. A change in the brand–generic mix can lower the margin even if the number of prescriptions and the effort required to serve patients do not change. A change in staffing can alter value added per pharmacist even when total pharmacy activity is stable. Portugal's reforms therefore changed the economic return to the same regulated service before the labor market had finished adjusting. They also occurred in a sector with other products and other employees: pharmacists make up roughly one-third of a typical pharmacy workforce, while technicians, clerical workers, and service staff make up the rest. The headline productivity measure is consequently best read as value available per pharmacist in the observed sector, not as a complete measure of every worker's contribution or of pharmacy service quality.
The timing reinforces the scale of the shock without making its components identical. Margin per prescription fell 17 percent between 2010 and 2011, before all of the later memorandum-era institutional changes took effect, and reached its 2014 low after further changes to generic substitution and margin formulas. That sequence means the wage outcome should not be attributed to a single contract clause or a single price rule. It is a case of several policy changes compressing the value pool over a short period, followed by a labor-market response that distributed the loss.
The labor-market response did not mirror the shock in the most obvious way. Average pharmacist wages fell by about one-third between 2009 and 2022, with the sharpest adjustment concentrated among people entering after the new contract rules took effect. Yet the number of pharmacists working in community pharmacies grew at close to 3 percent per year after 2009. The retail-pharmacy pharmacist workforce was at least 35 percent larger in 2022 than in 2009. Falling productivity, falling pay, and rising employment therefore appeared together.
That combination is the subject’s defining tension. It does not mean the sector was healthy, nor that every worker kept a job. It means that aggregate employment and worker welfare are different measurements. A pharmacy may close, a worker may change employers, and a newly qualified pharmacist may take the vacated or newly created position at a much lower wage. The sector’s headcount can rise even as the value of each job, and the bargaining position of the people entering it, deteriorates.
What “keeps hiring” does—and does not—mean
To make sense of the employment result, distinguish a workforce stock from the flows that change it. The stock is the number of pharmacists employed at a point in time. The flows include graduates entering the occupation, workers changing employers, people leaving, and positions disappearing when firms close or downsize. If the inflow is large enough, the stock can keep rising even when some workers are displaced and the wage offered to the next entrant falls.
That is what makes pharmacy a useful test case. Becoming a pharmacist requires occupation-specific education, and the study argues that qualified pharmacists had relatively few comparable opportunities outside the sector. At the same time, Portugal continued to produce new graduates. The integrated master's programs expanded the flow of graduates from about 530 a year in 2005–2007 to just over 800 in 2008, and the number stayed high through 2014. From 2012 to 2016, new graduate inflows accounted for roughly 5–6 percent annual increases in the workforce, while job churn contributed another 5–6 percent per year. Those flows were sufficient to keep adding workers even as older employers contracted and new hires joined on less favorable terms.
A simple benchmark helps show why the timing matters. If a typical pharmacist enters around age 28 and works until about age 60, an inflow equal to roughly 3 percent of the existing workforce can maintain a steady stock when there is no early attrition. An inflow near 6 percent can support growth of around 3 percent a year. The Portuguese pipeline was therefore large enough to mask the immediate effect of lower wages on headcount. People who had already chosen a long professional course did not instantly disappear from the labor supply when the wage outlook worsened, and the firms that remained open could draw on that pipeline. This is a lagged adjustment, not proof that wages have no influence on career choice.
The careful conclusion is therefore “little or no reduction in aggregate employment,” not “no layoffs.” The available evidence can show that the community-pharmacy workforce expanded; it cannot show that every pharmacist was protected from displacement or that all departures were voluntary. Nor does the main worker dataset provide a comparable view of hospital pharmacies, an important alternative employer that typically requires additional training. The observed result is strongest for private retail pharmacies, where about two-thirds of certified pharmacists work, not for every possible career destination of a Portuguese pharmacist.
This distinction also clarifies why the case is more informative than a simple story about wage flexibility. If workers could readily move to equally suitable jobs, a sector-wide wage cut might push them elsewhere and employment would fall. If employers could cut only headcount but not pay, the shock would appear as unemployment or firm exit. In Portugal’s pharmacies, the combination of specific training, bargaining coverage, firm turnover, and continuing graduate entry created another route: the sector could absorb a lower value per worker by paying less to the people most easily placed at the bottom of the wage structure.
A better way to read the shock
A two-tier wage system is not merely a description of inequality after the fact. It is an institution that determines who is asked to absorb a common loss and when. In 2012, the pharmacists’ sectoral agreement introduced a lower schedule for new hires, a lower entry floor, and slower progression through the experience categories. The rules also allowed some existing workers to move to the lower schedule in exchange for additional holidays. By 2018, more than 60 percent of pharmacists in the study were covered by the lower-tier arrangements. The details of floors, cushions, and promotions matter because they connect the industry’s lost value to the pay of particular cohorts.
Nor does “lower tier” mean that every affected worker received exactly the contractual floor. A floor is the minimum specified for a category; a worker may receive a cushion above it, along with supplements and premiums. Before the crisis, those additions commonly lifted base and total pay above the floor. After 2012, however, many new hires were paid below the customary floor cushion, and the new entry floor was about 24–25 percent below the earlier entry floor. A 2012 entrant paid at the contractual floor would earn about 30 percent less over the first five years than someone entering two years earlier, because the new schedule started lower and took longer to reach higher categories. The institution thus changed both the starting price of labor and the speed at which experience was rewarded.
The case can be held in one map:
The arrows should not be read as equally precise causal estimates. The study measures the reform period, the movement of margins and value added, the contractual changes, and the worker outcomes with linked administrative records. That combination is stronger than a single anecdote: the worker census supplies wages and hiring dates, firm records supply sales and value added, and bargaining records supply the rules. But it does not separately identify the contribution of every policy change, and some of its productivity measures require imputing value added for sole proprietorships. Its main wage-floor analysis also ends in 2018 because later records no longer identify the relevant collective-bargaining contracts. Owners, who account for about 14 percent of pharmacists, are excluded from the wage-earner sample, and hospitals are outside the comparable worker data. These boundaries do not erase the pattern; they define how far it can be carried.
The organizing relationships are now clear. Product-market rules changed what a pharmacy could earn from its regulated service. Collective bargaining determined how much of that loss could be reflected in contractual floors and promotion paths. The mix of incumbent workers and new entrants determined how quickly a lower tier changed the average wage. Graduate inflows and limited alternatives helped employment continue growing. Finally, a persistent relative wage loss could affect who applies to pharmacy programs and how attractive the occupation remains, even if that feedback arrives years after the original shock.
That sequence leads to a more useful judgment than either “the reforms caused layoffs” or “employment held up, so the adjustment was harmless.” Portugal’s pharmacies show that an industry can share a negative shock through wages rather than a simple collapse in headcount. But sharing the burden is not the same as sharing it evenly. The first unresolved link is upstream: before examining who paid through the contract, we need to see exactly how changes at the prescription counter took value out of the sector.